Search

Roche Holding AG

Geschlossen

BrancheGesundheitswesen

283.2 -0.07

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

279.6

Max

286

Schlüsselkennzahlen

By Trading Economics

Einkommen

1.7B

3.7B

Verkäufe

-15B

16B

KGV

Branchendurchschnitt

25.123

37.461

Dividendenrendite

3.28

Gewinnspanne

23.266

Angestellte

103,249

EBITDA

547M

6.5B

Dividenden

By Dow Jones

Dividendenrendite

Branchendurchschnitt

3.28%

2.33%

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

22B

227B

Vorheriger Eröffnungskurs

283.27

Vorheriger Schlusskurs

283.2

Roche Holding AG Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

23. Okt. 2025, 09:32 UTC

Ergebnisse

Roche Raises Full-Year Earnings Outlook as U.S. Drug-Pricing Talks Continue -- Update

23. Okt. 2025, 05:54 UTC

Ergebnisse

Roche Raises Full-Year Earnings Outlook

1. Okt. 2025, 08:54 UTC

Wichtige Markttreiber

Pharma Stocks in Europe Jump After White House Unveils Drug-Buying Site

18. Sept. 2025, 14:01 UTC

Akquisitionen, Fusionen, Übernahmen

Roche to Buy Maker of Fatty Liver Treatment 89bio for Up to $3.5 Billion -- 2nd Update

18. Sept. 2025, 10:05 UTC

Wichtige Markttreiber
Akquisitionen, Fusionen, Übernahmen

89bio Shares Soar Premarket on Takeover by Roche

18. Sept. 2025, 10:04 UTC

Akquisitionen, Fusionen, Übernahmen

Roche to Buy Maker of Fatty Liver Treatment 89bio for Up to $3.5 Billion -- Update

18. Sept. 2025, 05:37 UTC

Akquisitionen, Fusionen, Übernahmen

Roche to Buy 89bio for Up to $3.5 Billion

23. Okt. 2025, 09:19 UTC

Market Talk
Ergebnisse

Roche's Sales Slow, But Drug Pipeline Could Support Long-Term Growth -- Market Talk

23. Okt. 2025, 09:11 UTC

Market Talk
Ergebnisse

Roche Sales Miss Driven by Underperformance of Key Drugs -- Market Talk

23. Okt. 2025, 05:09 UTC

Ergebnisse

Roche 3Q Sales Up 6% At CER

23. Okt. 2025, 05:07 UTC

Ergebnisse

Roche 3Q Sales CHF14.92B

23. Okt. 2025, 05:07 UTC

Ergebnisse

Analysts Had Seen 3Q Sales At CHF15.17B

23. Okt. 2025, 05:07 UTC

Ergebnisse

Roche See Core Earnings Per Share Growth In High-Single to Low-Double-Digit Range At CER

23. Okt. 2025, 05:05 UTC

Ergebnisse

Roche Expects An Increase In Group Sales In Mid-Single-Digit Range At CER

23. Okt. 2025, 05:04 UTC

Ergebnisse

Roche: Group Sales Up 7% At Constant Exchange Rates In First Nine Months

23. Okt. 2025, 05:02 UTC

Ergebnisse

Roche Had Seen High-Single-Digit 2025 Core Earnings Per Share Growth at CER

23. Okt. 2025, 05:02 UTC

Ergebnisse

Roche Had Seen Mid-Single-Digit 2025 Sales Growth At Constant Exchange Rates

23. Okt. 2025, 05:02 UTC

Ergebnisse

Roche 9-Mos CH45.9B

23. Okt. 2025, 05:01 UTC

Ergebnisse

Roche Raises 2025 View

1. Okt. 2025, 20:33 UTC

Akquisitionen, Fusionen, Übernahmen

Roche Begins Tender Offer for 89bio Pursuant to Previously Announced Merger Agreement

1. Okt. 2025, 09:05 UTC

Heiße Aktien

Stocks to Watch Wednesday: Nike, Lithium Americas, Arm, Occidental -- WSJ

18. Sept. 2025, 14:12 UTC

Akquisitionen, Fusionen, Übernahmen

89bio Stock Soars 86%. Why Roche Is Buying the Biopharma Company for $3.5 Billion. -- Barrons.com

18. Sept. 2025, 07:37 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Roche's 89bio Acquisition Gives Its Drug Pipeline Potential Blockbuster -- Market Talk

18. Sept. 2025, 05:09 UTC

Akquisitionen, Fusionen, Übernahmen

89bio Says Deal Reflects Potential of Pegozafermin Drug Candidate

18. Sept. 2025, 05:06 UTC

Akquisitionen, Fusionen, Übernahmen

Roche: Deal Is Expected to Close in 4Q

18. Sept. 2025, 05:06 UTC

Akquisitionen, Fusionen, Übernahmen

Roche: Deal Enhanc Portfolio in Cardiovascular, Renal, Metabolic Diseases

18. Sept. 2025, 05:05 UTC

Akquisitionen, Fusionen, Übernahmen

Roche: MASH Is One of Most Prevalent Comorbidities of Obesity

18. Sept. 2025, 05:05 UTC

Akquisitionen, Fusionen, Übernahmen

Roche: 89bio Developing Potential Treatment for Metabolic Dysfunction-Associated Steatohepatitis

18. Sept. 2025, 05:04 UTC

Akquisitionen, Fusionen, Übernahmen

Roche to Buy 89bio for $14.50 a Share in Cash, Contingent Value Right of Up to $6 a Share

18. Sept. 2025, 05:03 UTC

Akquisitionen, Fusionen, Übernahmen

Roche: Total Deal Value Is Up to $3.5B

Roche Holding AG Prognose

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Roche Holding AG

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It is also developing products for various therapeutic areas. In addition, it offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases; diagnostic instruments; and digital health solutions. It has strategic discovery collaboration with Flare Therapeutics Inc. proteomic and mass spectrometry platform and expertise to discover novel small molecules aimed at transcription factor targets in oncology. Roche Holding AG was founded in 1896 and is based in Basel, Switzerland.
help-icon Live chat